Open

Coming up

Don't miss

Replay


LATEST SHOWS

WEB NEWS

Online movement demands peace in Gaza

Read more

BUSINESS DAILY

Apple aims to satisfy China's hunger for smartphones

Read more

DEBATE

MH17: Punishing Putin? (part two)

Read more

DEBATE

MH17: Punishing Putin?

Read more

MEDIAWATCH

Competing narratives in Malaysia Airlines disaster coverage

Read more

AFRICA NEWS

Kenya : Police arrest 8 over Mombasa rampage

Read more

FOCUS

Overfishing and the global appetite for bluefin tuna: can Tokyo turn the tide?

Read more

MEDIAWATCH

Too many graphic images from Gaza ?

Read more

FASHION

Who's next in Paris, an event with international ready-to-wear and fashion accessories collections

Read more

  • Netherlands to honour MH17 victims in national day of mourning

    Read more

  • Defying UK, France to proceed with warships sale to Russia

    Read more

  • Israel hits Gaza targets despite diplomatic push for ceasefire

    Read more

  • US courts issue conflicting reports on Obamacare

    Read more

  • Video: Lebanon fears fallout from regional turmoil

    Read more

  • Widodo wins Indonesian presidential election

    Read more

  • Flight MH17 shot down ‘by mistake', US intelligence indicates

    Read more

  • US, European airlines suspend flights to Tel Aviv

    Read more

  • Australian veteran Rogers claims 16th stage of Tour de France

    Read more

  • France gives go-ahead to pro-Palestinian Paris rally

    Read more

  • French Jews mourn French-Israeli soldier killed in Gaza

    Read more

  • PSG punished by UEFA for abuse of disabled Chelsea fans

    Read more

  • Colombia's Rodriguez signs '€80m' contract with Real Madrid

    Read more

  • Children killed in minibus crash in eastern France

    Read more

  • A call for harmony in riot-hit ‘Little Jerusalem’ Paris suburb

    Read more

Health

Doctors start first human trial of stem cells

Text by News Wires

Latest update : 2010-10-11

US doctors have begun testing human stem cells on a patient for the first time after securing a license to use the controversial cells to treat people with spinal injuries.

AFP - US doctors have begun treating the first patient with embryonic stem cells as part of the first human study of the controversial treatment authorized by the government, the Geron Corporation said Monday.
  
The patient was enrolled at the Shepherd Center spinal cord and brain injury rehabilitation hospital in Atlanta, Georgia, where Geron began clinical trials of their GRNOPC1 human embryonic stem cells in treating patients with devastating spinal cord injuries.
  
The trial comes just 11 years after Geron began working with human embryonic stem cells in 1999, when "many predicted that it would be a number of decades before a cell therapy would be approved for human clinical trials," said Thomas Okarma, Geron's president and CEO.
  
"Initiating the GRNOPC1 clinical trial is a milestone for the field of human embryonic stem cell-based therapies," Okarma said.
  
Geron got clearance in January last year to conduct human trials of GRNOPC1 embryonic stem cells, which are highly versatile, primitive cells capable of developing into any tissue.
  
Preclinical studies have shown that GRNOPC1 significantly improved locomotor activity of animals with spinal cord injuries when injected seven days after the injury.
  
Participants in the study must be newly injured and receive GRNOPC1 between seven and 14 days of sustaining their injury.
  
David Apple, Shepherd Center's medical director, said the clinical trial was a key step forward in attempts to find a cure for paralysis in people with spinal cord injury.
  
The ultimate goal is to inject GRNOPC1 cells into the spines of paralyzed human volunteers in the hope that this will prompt damaged nerve cells to regrow, enabling the patients to eventually recover feeling and movement.

Date created : 2010-10-11

  • USA

    Court lifts ban on funding for embryonic stem cell research

    Read more

  • BIOETHICS

    South Korean stem cell scientist convicted for faked research

    Read more

COMMENT(S)